Next Article in Journal
Transcriptome Analysis of Salt Stress in Hibiscus hamabo Sieb. et Zucc Based on Pacbio Full-Length Transcriptome Sequencing
Next Article in Special Issue
Localization and Absolute Quantification of Dopamine in Discrete Intravesicular Compartments Using NanoSIMS Imaging
Previous Article in Journal
Nutraceuticals Synergistically Promote Osteogenesis in Cultured 7F2 Osteoblasts and Mitigate Inhibition of Differentiation and Maturation in Simulated Microgravity
Previous Article in Special Issue
Complement System in Alzheimer’s Disease
 
 
Review
Peer-Review Record

The ABCs of Antigen Presentation by Stromal Non-Professional Antigen-Presenting Cells

Int. J. Mol. Sci. 2022, 23(1), 137; https://doi.org/10.3390/ijms23010137
by Tom J. Harryvan 1,*, Sabine de Lange 1, Lukas J.A.C. Hawinkels 1,*,† and Els M.E. Verdegaal 2,*,†
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2022, 23(1), 137; https://doi.org/10.3390/ijms23010137
Submission received: 30 November 2021 / Revised: 20 December 2021 / Accepted: 22 December 2021 / Published: 23 December 2021
(This article belongs to the Special Issue 25th Anniversary of IJMS: Advances in Biochemistry)

Round 1

Reviewer 1 Report

Authors should discuss/incorporate the below points in the manuscript

1. Authors should describe the role of non-professional antigen presenting cells in others diseases alongwith cancer.

2.Spell check is needed to correct the typo errors. e.g. MCH

3. How professional antigen presenting cells are superior over non-professional cells.

4. Can these non professional antigen presenting cell be modified to treat the diseases?

Author Response

Our point-to-point response to Reviewer 1 has been attached ('Reviewer 1 revision_final.docx').

Author Response File: Author Response.docx

Reviewer 2 Report

Harryvan et al. provide a survey over stromal cells being able to present antigens with and/or without co-stimulation. The former have a role in autoimmunity and possible antitumoral responses, the latter in thymus-independent tolerance due to the key mechanism of anergy. The review is comprehensively written, naming possible white spots and allowing to draw further hypotheses for further descriptive and mechanistic studies. I only have few minor points.

Minor issues:

  • Line 62: The content of quotes 6,7 (reviews) is already mentioned in citation 4 (Joffre et al).
  • Line 120: Here, “CAF” is mentioned for the first time (check together with line 169).
  • Line 121: “…MHCII[23], have been first identified in pancreatic ductal adenocarcinoma (PDAC).” -> …MHCII, have been first identified in pancreatic ductal adenocarcinoma (PDAC)[23].
  • Lines 179-189 and 190-192: Please briefly clarify where your data relies on in vivo, ex vivo and in vitro experiments.
  • Line 213: “…were show..” -> were shown.
  • Line 313: “…, potentiating cytotoxic T cell function.” Please add quote.
  • Line 402: “…antigens5.” Please check quote.

Author Response

Our point-to-point response to Reviewer 1 has been attached ('Reviewer 2 revision_final.docx').

Author Response File: Author Response.docx

Back to TopTop